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The abrupt outbreak of the COVID-19 pandemic in Italy began on 20 February 2020, with the first
patient developing severe acute respiratory syndrome in Lombardy (northern Italy). On 11 March 2020,
the World Health Organization declared the pandemic state,1 and Italy was the third most affected
country, after the United States and Spain, at the time of writing.2,3 Lombardy was particularly affected,
with 984 positive cases in the first week and 50455 cases after 6 weeks, whereas the rest of Italy,
particularly the central and southern regions, faced about one tenth of the number of cases.4 The rapidly
evolving situation left only a short time to adopt effective measures aimed at limiting the spread of
COVID-19, particularly in hospitals among patients and health care professionals (HCPs). Hospitals
started to reorganize into intensive care units (ICUs) to manage COVID-191 cases, and most decisions
were made at a single-center level and in a “day-by-day” manner. Hematology care is particularly
complex because it deals with malignant and benign diseases, rare conditions, highly expensive drugs,
and life-saving nondeferrable therapies. Hematological patients are often elderly, highly comorbid, and
immunocompromised,5 and they experience an annual mortality peak that is caused by seasonal
influenza.6 In this setting, knowledge of the best preventive measures to adopt during a pandemic is
crucial, because hematologic patients may be affected more by COVID-19 and, at the same time, be
a focus of further spread.5 This article reports the strategies of progressive systematic reorganization of
hematologic care in a large public university hospital in Milan (Lombardy) during the first 6 weeks of the
COVID-19 pandemic. At this site, 4750 adult patients (median age, 67 years; range, 28%-96; 56%
males), almost all of whom were diagnosed with hematological diseases, including malignant conditions
(n 5 3900), benign conditions (n 5 650), and rare diseases (n 5 550), are actively followed. Typically,
18 831 routine visits, 9930 day-hospital care services, and 436 admissions to the wards occur annually.
The health care staff includes physicians (21 consulting hematologists and 8 fellows), 36 nurses, 14
biologists, and 5 technicians operating at 4 main facilities: outpatient clinics (divided into 8 disease-
specific groups, all open Monday through Friday), day-hospital care services, 1 hematology ward, 1
transplant ward, and 2 laboratories (1 for diagnosis and research on malignant conditions and 1 for rare
anemias). There is also a trial office, including 4 data managers (biologists), a pharmacologist, and a trial
nurse; a total of 76 trials (observational and interventional) are ongoing. This study was conducted in
accordance with the Declaration of Helsinki, and each participant provided written informed consent for
data collection during routine evaluation/follow-up.
As shown in Table 1, the number of clinical services decreased by;10% during the first 2 weeks of the
pandemic, stabilized during weeks 3 and 4, and decreased by 17% during the last 2 weeks. Specifically,
outpatient visits decreased by a median of 48% (range, 28.9%-59.4%) from baseline to week 6,
exceeding a 50% decrease by week 4. Scheduled, but deferrable, first hematological consultations
were cancelled; only urgent appointments were accepted. The criteria for deferring routine outpatient
visits were malignancies off treatment or on maintenance, autoimmune cytopenias on steroid tapering/
stable immunosuppressive therapy, and benign conditions not requiring treatment. Moreover, some
patients decided on their own to cancel/postpone their appointments. With regard to day-care service,
a progressive reduction in global activity occurred (median, 18%; range, 4.4%-31.4%), with the greatest
decrease by week 5. A total of 44 nonurgent therapies/procedures were deferred, whereas therapies for
acute leukemia (AL), aggressive Hodgkin lymphomas (NHL), and Hodgkin lymphomas were not delayed.
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Of note, an initial decrease was observed in the first week as a result
of the chaotic situation and the fear experienced by patients and
HCPs; activities temporarily recovered during the second and third
weeks. Seventeen nonurgent bone marrow samplings were post-
poned. Urgent transfusions were guaranteed, and transfusion-
dependent patients adapted their schedules to fit with donor
availability (1 unit per week instead of 2 units per 14 days), because
the transfusion center experienced a marked reduction in donors.
With regard to hospitalization, admissions to the hematology and
transplant wards showed a decrease at week 1; thereafter, the
limited number of admissions did not allow for definitive conclusions
to be made (paradoxical increase, as shown in Table 1). With regard
to reallocation of HCPs, from 24 February 2020, hematology/
transplant wards were separated from the internal medicine wards,
where potentially COVID-191 patients could be admitted from the
Emergency Department. In the general reorganization of the
hospital, some personnel from the hematology unit were reass-
signed to COVID-191 wards. From 2 March 2020, laboratory and
trial office on-site personnel were reduced, and telecommuting was
instituted.
Figure 1A shows the progressive adoption of personal protective
equipment (PPE) starting with surgical masks and disposable
gloves and proceeding to filtering face piece-2 masks, protective
eye goggles, and water-repellent disposable coats. The waiting
room of the outpatient clinic was reorganized to guarantee social
distancing (2 m), with limited access for relatives/caregivers. From
16 March 2020, body temperature and history of symptoms were
recorded every day for anyone (HCPs and visitors) at the entrance
of the clinic/day service. Suspected cases were isolated in
a protected area before medical evaluation and the naso-
pharingeal swab results (performed in a dedicated room that was
sanitized every day). Outpatients were tested if symptomatic for
COVID-19 or if they had to be admitted to the hematology/
transplant ward. The procedure allowed us to identify 2 positive
cases among symptomatic outpatients; all patients to be admitted
were negative (Figure 1B). All HCPs were tested at week 6, with
negative results. Overall, the progressive adoption of protective
measures and careful anamnesis of symptoms and contacts
appeared to be useful to identify potential positive cases, whereas
the systematic use of nasal-pharyngeal swabs, although useful, is
affected by low sensitivity.7
A progressive implementation of telemedicine was adopted. As
shown in Figure 1C, the number of e-mails and telephone calls
increased, along with a decrease in outpatient visits. A total of 2530
contacts aimed at evaluating patients’ external laboratory/radiology
results and/or at giving specific advice/prescriptions on medica-
tions/procedures were recorded. Home sampling performed by
nurses of the hematology unit was interrupted to prevent patient/
HCP exposure, whereas patients were favorably sampled at
external local laboratories. Hospital-distributed drugs (proteasome,
BCL2, and TK inhibitors; thrombopoietin analogs; and recombinant
erythropoietin) were delivered via hospital pharmacy during the first
2 weeks and through a home delivery service thereafter.
As of 5 April 2020, 26 patients on active follow-up tested positive
for COVID-19: 6 with myelodysplastic syndrome, 6 with chronic
lymphocytic leukemia, 4 with NHL, 3 with myeloproliferative
neoplasm, 3 with AL, 2 with MM, and 2 with autoimmune hemolytic
anemia. Almost all patients (22/26) required admission to the
hospital, 4 of whom were admitted to the ICU. Treatments included
oxygen and/or ventilation support, antibiotics, hydroxychloroquine,
steroids, and tocilizumab. Six patients had to discontinue their
hematological drugs, including 2 subjects enrolled in a clinical trial.
Six patients (23%) died; all were males, and 5 of 6 were older than
Table 1. Clinical activities of the hematology unit before and during the COVID-19 pandemic
Services Baseline, n Week 1 (24 Feb) Week 2 (2 Mar) Week 3 (9 Mar) Week 4 (16 Mar) Week 5 (23 Mar) Week 6 (30 Mar)
Total services 743.8 672 (210) 686 (28) 738 (21) 712 (24) 634 (215) 599 (219)
Outpatients visits 446.2 312 (230) 317 (229) 256 (243) 208 (253) 181 (259) 193 (257)
Day-hospital care accesses 288.6 239 (217) 270 (26) 276 (24) 236 (218) 198 (231) 201 (230)
Transfusions* 70.3 60 (215) 55 (222) 63 (210) 54 (223) 53 (225) 49 (230)
Therapies† 136.6 102 (225) 174 (127) 157 (115) 123 (210) 107 (222) 102 (225)
Bone marrow‡ 32.6 23 (229) 22 (232) 25 (223) 25 (223) 15 (254) 15 (254)
Other§ 40.3 54 (134) 19 (253) 31 (223) 34 (216) 23 (243) 35 (213)
New admissions to hematology ward 5 5 (0) 4 (220) 8 (160) 6 (120) 6 (120) 6 (120)
New admissions to transplant ward{ 4 3 (225) 5 (125) 2 (250) 3 (225) 2 (250) 4 (0)
Unless otherwise noted, all data are n (percentage change from baseline). The mean for the 3 weeks preceding the COVID-19 pandemic was used as the baseline value.
*Transfusions are intended as the number of patients receiving transfusions.
†Therapies performed included the following drugs or schemes: adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD), bendamustine, gemcitabine, and vinorelbine (BEGEV),
cyclophosphamide, doxorubicine, etoposide, vincristine, and prednisolone (CHEOP), rituximab, cyclophosphamide, doxorubicine, vincristine, and prednisolone (R-CHOP), rituximab,
cyclophosphamide, lyposomial doxorubicine, vincristine, and prednisolone (R-COMP), gemcitabine, oxalyplatinum, and prednisolone (GDP), carfilzomib, lenalidomide, dexamethazone (KRD),
rituximab, bendamustine, blinatumomab, bortezomib, brentuximab, daratumumab, decitabine, azacitidine, obinutuzumab, cyclophosphamide, elotuzumab, and arsenic trioxide (TRISENOX), and
eculizumab. The following therapies were deferred: 3 chemoimmunotherapy cycles for indolent NHL, 17 biologic drugs (4 bortezomib, 12 carfilzomib, 1 daratumumab) for MM and
amyloidosis, and 2 hypomethylating agents (azacitidine) for high-risk myelodysplastic syndrome (MDS). Lenalidomide maintenance was interrupted in 5 MM patients, all in long-term
remission.
‡Reasons for bone marrow deferral were routine follow-up of AL (n 5 2) and myeloproliferative neoplasms (n 5 4), staging of indolent NHL (n 5 5), evaluation of monoclonal gammopathy
of undetermined significance (n 5 3), and reevaluation of immune thrombocytopenia, aplastic anemia, and low-risk MDS (n 5 1 each).
§Other procedures included IV hydration, phlebotomy, IV immunoglobulin, albumin infusions, lumbar punctures, and venetoclax ramp-up.
{Two allogeneic nonurgent transplants for cutaneous NHL were postponed (1 because of the inability to receive the donor’s stem cells from Australia, and 1 because of the temporary
unavailability of ICU support). However, 4 allogeneic transplants for acute myeloid leukemia (3 haploidentical and 1 matched unrelated donor) and 5 autologous transplants for MM were
performed during the study period.
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80 years of age. Mortality was nearly comparable to that of patients
admitted to the ICU.8 Although this is beyond the scope of this
article, positive cases within the hematology unit (26/4750; 0.5%)
were constantly changing, and estimated to be what was observed
in Lombardy as of 3 April (46 065/10 019166; 0.5%). Among
health care workers, 5 nurses and 3 biologists tested positive for
COVID-19 (all tested and likely infected during shifts outside of the
hematology unit).
In summary, the narrative description of our experience shows the
safety and feasibility of care for hematological patients during
pandemics and advocates for an earlier adoption of the highest level
of preventive measures at the pandemic’s beginning. We advise
prompt and systematic use of PPE, separation of hematological
wards and shifts, anamnesis of symptoms and contacts, time/
space and social limitations, and telemedicine practices. This
would limit the spread of the infection among patients and
workers, ensure the continuity of care, and allow the delivery of
life-saving therapies/transfusions to urgent patients with aggres-
sive diseases.
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Figure 1. Modification of clinical activities during
COVID-19 pandemic. (A) Protective measures adop-
ted during the study period. (B) Number of tests
performed on patients in the Hematology Department
and rate of positivity during the study. (C) Outpatients
visits and telemedicine trends during the study. All
evaluations were calculated as “total observations per
week” and compared with the routine numbers pre-
ceding COVID-19 infection. The latter were calculated
as mean number per week considering the 3 weeks
preceding February 24 2020. With regard to tele-
medicine before the pandemics, e-mails and phone
calls received for medical reasons represented ;3%
of our practice. FFP2, filtering facepiece 2; T°,
temperature.
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